Barclays’s Meridian Bioscience Inc VIVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-900
| Closed | -$8K | – | 6430 |
|
|
2020
Q1 | $8K | Buy |
+900
| New | +$7.58K | ﹤0.01% | 5880 |
|
|
2018
Q2 | – | Sell |
-300
| Closed | -$4K | – | 7411 |
|
|
2018
Q1 | $4K | Hold |
300
| – | – | ﹤0.01% | 6832 |
|
|
2017
Q4 | $4K | Buy |
+300
| New | +$4.39K | ﹤0.01% | 6714 |
|
|
2017
Q2 | – | Sell |
-800
| Closed | -$11K | – | 7040 |
|
|
2017
Q1 | $11K | Sell |
800
-2,500
| -76% | -$35K | ﹤0.01% | 6058 |
|
|
2016
Q4 | $58K | Sell |
3,300
-2,700
| -45% | -$47.4K | ﹤0.01% | 5076 |
|
|
2016
Q3 | $116K | Buy |
6,000
+4,000
| +200% | +$78.3K | ﹤0.01% | 4406 |
|
|
2016
Q2 | $39K | Buy |
2,000
+1,500
| +300% | +$29.4K | ﹤0.01% | 4972 |
|
|
2016
Q1 | $10K | Buy |
+500
| New | +$9.85K | ﹤0.01% | 5483 |
|
|
2015
Q4 | – | Sell |
-2,000
| Closed | -$34K | – | 6753 |
|
|
2015
Q3 | $34K | Sell |
2,000
-2,300
| -53% | -$42K | ﹤0.01% | 5218 |
|
|
2015
Q2 | $77K | Sell |
4,300
-1,000
| -19% | -$18.5K | ﹤0.01% | 4866 |
|
|
2015
Q1 | $101K | Buy |
5,300
+1,300
| +33% | +$24K | ﹤0.01% | 4851 |
|
|
2014
Q4 | $64K | Sell |
4,000
-4,700
| -54% | -$80.6K | ﹤0.01% | 5518 |
|
|
2014
Q3 | $148K | Buy |
8,700
+7,200
| +480% | +$141K | ﹤0.01% | 5007 |
|
|
2014
Q2 | $30K | Buy |
1,500
+100
| +7% | +$2.06K | ﹤0.01% | 6293 |
|
|
2014
Q1 | $29K | Buy |
+1,400
| New | +$32.1K | ﹤0.01% | 6393 |
|
|
2013
Q4 | – | Sell |
-1,100
| Closed | -$25K | – | 7734 |
|
|
2013
Q3 | $25K | Sell |
1,100
-200
| -15% | -$4.67K | ﹤0.01% | 6434 |
|
|
2013
Q2 | $28K | Buy |
+1,300
| New | +$28K | ﹤0.01% | 6669 |
|
Other funds holding VIVO
Barclays's VIVO Position: Q1 2023 in Review
Barclays sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 50,293 shares — an estimated $1.67M sold.
Barclays first reported a position in VIVO in Q2 2013 and held it in 37 quarters. The position peaked at $1.67M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.
- Barclays reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
- Barclays sold 50,293 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.67M.
- Barclays first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 37 quarters.
- Barclays's Meridian Bioscience Inc position peaked at $1.67M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.